Growth Hormone News and Research RSS Feed - Growth Hormone News and Research

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.
Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy--a more precise form of radiotherapy--to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research published in The Lancet Oncology journal today. [More]
Study focuses on parents' perceptions of risks, benefits of treating children with short stature

Study focuses on parents' perceptions of risks, benefits of treating children with short stature

A new study led by pediatric endocrinologist Adda Grimberg, M.D., of The Children's Hospital of Philadelphia, proposes to reframe the debate. "We set out to answer a new question," said Grimberg. "What are the factors, perceived or real, that drive some families to seek medical care for short stature?" [More]
Rotation model provides explanation of ligand activation mechanism of dimeric receptors

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

"This 'rotation model', which made the cover of BioEssays, represents a true paradigm shift in the membrane receptor field," stated Prof. Pierre De Meyts, a renowned researcher of insulin and receptor binding for almost half a century and one of the reviewers of the paper by Prof. Ichiro Maruyama, the head of the Information Processing Biology Unit at Okinawa Institute of Science and Technology Graduate University. [More]
Latitude, summer daylight exposure make difference in results for children treated with growth hormone

Latitude, summer daylight exposure make difference in results for children treated with growth hormone

The rate of growth in children varies with the season while higher latitude and greater summer daylight exposure makes a significant difference in results for children treated with growth hormone, according to new research from The University of Manchester. [More]
Frost & Sullivan honours recipients of 2015 Excellence in Best Practices Awards

Frost & Sullivan honours recipients of 2015 Excellence in Best Practices Awards

On Thursday, October 22, Frost & Sullivan honoured recipients of its 2015 Excellence in Best Practices Awards Banquet in Monaco. With a festive ambiance and exciting Awards, the event brought together top executives to celebrate their success. [More]
Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

A recent publication, which received sustained media attention, claimed that most cancers are just “bad luck”. Its authors stated that only about one-third of cancer mutations are caused by known lifestyle or environmental factors. [More]
No lasting metabolic health costs from combined GH and GnRH analogue therapy

No lasting metabolic health costs from combined GH and GnRH analogue therapy

Gonadotropin-releasing hormone analogue given alongside growth hormone during puberty in order to increase adult height does not have long-term metabolic health consequences in children born small for gestational age, research shows. [More]
Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae are common following paediatric low-grade gliomas affecting the optic pathway, hypothalamus and suprasellar areas and are influenced by tumour location and treatment choice, a study shows. [More]
Signs of Alzheimer’s found in growth hormone patients

Signs of Alzheimer’s found in growth hormone patients

People may be able to contract Alzheimer’s disease during certain medical procedures in the same way that Creutzfeldt-Jakob disease (CJD) is transmitted, suggest researchers from University College London. [More]
Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Since the classical studies of Jacob and Monod in the early 1960s, it has been evident that genome sequences contain not only blueprints for genes and the proteins that they encode, but also the instructions for a coordinated regulatory program that governs when, where and to what extent these genes and proteins are expressed. [More]
Girls are born with weaker spines compared to boys, study finds

Girls are born with weaker spines compared to boys, study finds

Looking at measurements of the vertebrae - the series of small bones that make up the spinal column - in newborn children, investigators at Children's Hospital Los Angeles found that differences between the sexes are present at birth. Results of the study, now online in advance of publication in the August issue of the Journal of Pediatrics, suggest that this difference is evolutionary, allowing the female spine to adapt to the fetal load during pregnancy. [More]
Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
Aeterna Zentaris selects Ergomed to manage Phase 3 clinical study of Macrilen

Aeterna Zentaris selects Ergomed to manage Phase 3 clinical study of Macrilen

Aeterna Zentaris Inc. announced today that it has executed a definitive agreement with Ergomed PLC, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD"). [More]
Novo Nordisk presents new data detailing the impact of hemophilia on patients, caregivers

Novo Nordisk presents new data detailing the impact of hemophilia on patients, caregivers

Today, Novo Nordisk presented new data detailing the impact hemophilia has on both caregivers and those living with the disease. [More]
Researchers find persistent gender bias in provision of growth hormone treatment for idiopathic short stature

Researchers find persistent gender bias in provision of growth hormone treatment for idiopathic short stature

Short boys are three times more likely than short girls to receive recombinant human growth hormone treatment for idiopathic short stature (ISS), even though in a general pediatric population, equal proportions of both genders fall under the height threshold designating ISS. Researchers who analyzed records of over 283,000 U.S. children and adolescents found a clear-cut and persistent gender bias in the provision of treatment. [More]
Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial. [More]
Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

Funding from the Mark Cuban Foundation, run by the well-known owner of the Dallas Mavericks, will allow University of Michigan scientists and physicians to study how human growth hormone may aid recovery from an ACL tear - one of the most frequent, traumatic and dreaded knee injuries among athletes. [More]
Advertisement
Advertisement